AR134366A1 - Anticuerpo antitranstiretina, composiciones que comprenden dicho anticuerpo y métodos para tratar o prevenir la amiloidosis mediada por transtiretina - Google Patents

Anticuerpo antitranstiretina, composiciones que comprenden dicho anticuerpo y métodos para tratar o prevenir la amiloidosis mediada por transtiretina

Info

Publication number
AR134366A1
AR134366A1 ARP240103147A ARP240103147A AR134366A1 AR 134366 A1 AR134366 A1 AR 134366A1 AR P240103147 A ARP240103147 A AR P240103147A AR P240103147 A ARP240103147 A AR P240103147A AR 134366 A1 AR134366 A1 AR 134366A1
Authority
AR
Argentina
Prior art keywords
methods
antibody
compositions
treating
preventing
Prior art date
Application number
ARP240103147A
Other languages
English (en)
Inventor
Aubin Michalon
Michael Salzmann
Rahul Godawat
Siguang Sui
Original Assignee
Neurimmune Ag
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurimmune Ag, Alexion Pharma Inc filed Critical Neurimmune Ag
Publication of AR134366A1 publication Critical patent/AR134366A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anticuerpos antitranstiretina (TTR), polinucleótidos correspondientes y vectores de expresión, así como composiciones (por ejemplo, composiciones farmacéuticas) y artículos de elaboración relacionados que contienen el anticuerpo anti-TTR como un fármaco. También métodos para tratar o prevenir la amiloidosis mediada por transtiretina (ATTR) en un sujeto que lo necesite con el uso de las composiciones farmacéuticas. Además, métodos para validar, identificar y cribar un fármaco que disminuye los amiloides con el uso de formación de imágenes de células vivas de alta resolución, así como métodos para producir una composición farmacéutica de un fármaco que disminuye los amiloides y kits adecuados para su uso en dichos métodos.
ARP240103147A 2023-11-15 2024-11-15 Anticuerpo antitranstiretina, composiciones que comprenden dicho anticuerpo y métodos para tratar o prevenir la amiloidosis mediada por transtiretina AR134366A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2023081969 2023-11-15
EP2024064293 2024-05-23
EP2024077454 2024-09-30

Publications (1)

Publication Number Publication Date
AR134366A1 true AR134366A1 (es) 2026-01-07

Family

ID=93562471

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240103147A AR134366A1 (es) 2023-11-15 2024-11-15 Anticuerpo antitranstiretina, composiciones que comprenden dicho anticuerpo y métodos para tratar o prevenir la amiloidosis mediada por transtiretina

Country Status (3)

Country Link
AR (1) AR134366A1 (es)
TW (1) TW202528347A (es)
WO (1) WO2025104243A1 (es)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
BR9808584A (pt) 1997-03-14 2000-05-23 Idec Pharma Corp Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
CA2429544C (en) 2000-11-17 2010-10-19 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
WO2014058389A1 (en) 2012-10-12 2014-04-17 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
AU2013372331A1 (en) * 2013-01-10 2015-07-23 Genmab B.V. Human IgG1 Fc region variants and uses thereof
EP2953970A4 (en) 2013-02-08 2016-06-29 Misfolding Diagnostics Inc TRANSTYRETIN ANTIBODIES AND USES THEREOF
WO2015092077A1 (en) 2013-12-20 2015-06-25 Neurimmune Holding Ag Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI718122B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
AU2018375356A1 (en) * 2017-11-29 2020-05-14 Neotope Neuroscience Limited Lyophilized formulation of a monoclonal antibody against transthyretin
US20210400932A1 (en) 2018-11-09 2021-12-30 Neurimmune Ag Patient-derived amyloid xenograft non-human animal model
TW202106708A (zh) * 2019-04-24 2021-02-16 美商銳進科斯生物股份有限公司 全人類轉譯後修飾之抗體治療劑
CN115551886A (zh) 2020-05-12 2022-12-30 生物控股有限公司 用于ttr淀粉样变性的联合疗法
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
CN120322454A (zh) 2022-11-15 2025-07-15 神经免疫有限公司 用于治疗或预防转甲状腺素蛋白介导的淀粉样变性的药物组合物

Also Published As

Publication number Publication date
WO2025104243A1 (en) 2025-05-22
TW202528347A (zh) 2025-07-16

Similar Documents

Publication Publication Date Title
McLure et al. A comparative HST imaging study of the host galaxies of radio-quiet quasars, radio-loud quasars and radio galaxies—I
CY1121162T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου
CL2021000293A1 (es) Anticuerpos anti-trem2 y métodos relacionados (divisional de solicitud no.202001575)
CL2024002658A1 (es) Moléculas de unión contra fralfa
CL2021001541A1 (es) Un complejo novedoso que comprende un péptido penetrante de células, una carga y un agonista de péptido de tlr para tratamiento de cáncer colorrectal (divisional de la solicitud no. 201900694)
CL2010000791A1 (es) Anticuerpo monoclonales que se unen a integrina alfavbeta6 (7.7g5), composicion; hibridoma que lo produce (atcc pta-3899); usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros. (divisional solicitud n° 513-03)
MX2022008214A (es) Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl.
MX2021013657A (es) Conjugados de anticuerpo y farmaco.
MX2024005727A (es) Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3.
MX2023005381A (es) Conjugados de anticuerpo y farmaco.
AR128060A1 (es) Complejos polipeptídicos de unión a antígeno activados condicionalmente y métodos de uso de los mismos
CO2022018547A2 (es) Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CL2023000084A1 (es) Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas
CL2025001171A1 (es) Compuestos que median la degradacion de proteinas y metodos de uso de los mismos
Samuelson et al. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis
CO2024000890A2 (es) Compuestos de heteroarilo para tratar la enfermedad de huntington
CL2026000399A1 (es) Conjugados de neodegradador-anticuerpo anti-cd33.
Mitta et al. A new morphotype of lower jaw associated with Calliphylloceras (Cephalopoda: Ammonoidea) from the Middle Jurassic of the Northern Caucasus
Zawar et al. Nail changes due to chemotherapy: a prospective observational study of 129 patients
CL2023002992A1 (es) Anticuerpos anti-c-met y conjugados de anticuerpo-fármaco
AR008781A1 (es) Compuestos de furano nitrona
Linauskienė et al. Solvent Orange 60 is a potent contact sensitizer in occupational and everyday life
Lin et al. Cytotoxic and biomechanical effects of clinical dosing schemes of paclitaxel on neurons and cancer cells
Khan Archaeological Tourism and Heritage Management: A Case Study of Taxila Valley